shadow shadow shadow shadow shadow
    Country
    Opportunity Status
    Funding Instrument Type
    Category
    Clear

    Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)

    PAR-24-043

    National Institutes of Health

    Opening date 2 Nov 2023, 12:00AM

    Closing date 18 Aug 2026, 12:00AM

    Funding Opportunity Number: PAR-24-043

    Opportunity Category: Discretionary

    CFDA Number(s): 93.121 -- Oral Diseases and Disorders Research,93.213 -- Research and Training in Complementary and Integrative Health,93.242 -- Mental Health Research Grants,93.273 -- Alcohol Research Programs,93.279 -- Drug Abuse and Addiction Research Programs,93.853 -- Extramural Research Programs in the Neurosciences and Neurological Disorders,93.865 -- Child Health and Human Development Extramural Research,93.866 -- Aging Research,93.867 -- Vision Research

    Cost Sharing or Matching Requirement: No

    Posted Date: Nov 02, 2023 12:00:00 AM EDT

    Closing Date: Aug 18, 2026 12:00:00 AM EDT

    Award Ceiling: none

    Award Floor: none

    Eligible Applicants: Independent school districts,Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education,Others (see text field entitled "Additional Information on Eligibility" for clarification),Private institutions of higher education,State governments,Public housing authorities/Indian housing authorities,Native American tribal governments (Federally recognized),Special district governments,County governments,Public and State controlled institutions of higher education,Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education,For profit organizations other than small businesses,City or township governments,Small businesses,Native American tribal organizations (other than Federally recognized tribal governments)

    Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

    Agency Name: National Institutes of Health

    Description: Reissue of PAR-18-546. The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry to the Development stage, to advance a single development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Alternatively, projects can enter at the Development stage and progress in a shorter period to IND enabling toxicology studies and phase I clinical testing. BPN awardee Institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.

    Grantor Contact Information: NIH Grants Information grantsinfo@nih.gov

    We use cookies and similar technologies that are necessary to operate the website.Please read our cookie policy.

    We use cookies and similar technologies that are necessary to operate the website. Additional cookies are only used with your consent. We use the additional cookies to perform analyses of website usage and to check marketing measures for their efficiency. These analyses are carried out to provide you with a better user experience on the website. You are free to give, deny, or withdraw your consent at any time by using the "cookie settings" link at the bottom of each page. You can consent to our use of cookies by clicking "Agree". For more information about what information is collected and how it is shared with our partners, please read our cookie policy.

    • Required to run the website
    • Monitoring website usage and optimizing the user experience
    • Evaluation of marketing actions
    • Storage of your preferences from previous visits
    • Collecting user feedback to improve our website
    • Recording of your interests in order to provide customised content and offers
    Cookie Settings Accept